SCHEMBL30890449

SCHEMBL30890449

C[C@H](N)C(=O)N(C)[C@@H](CC1CC1)C(=O)N1C[C@@]2(C[C@H]1C(N)=O)Oc1cc(F)cc(F)c1NC2=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27245008 0.92 — —
SCHEMBL27245016 0.92 — —
SCHEMBL27245143 0.91 — —
SCHEMBL27245140 0.91 — —
SCHEMBL27244837 0.89 — —
SCHEMBL27244830 0.89 — —
SCHEMBL27245132 0.89 — —
SCHEMBL27245128 0.89 — —
SCHEMBL27244997 0.88 — —
SCHEMBL30992245 0.88 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024097296-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
Send feedback